Tenaya Therapeutics, Inc. (TNYA) Stock Score, Valuation & Financial Research

Tenaya Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for TNYA

Tenaya Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.57. These figures are a research snapshot, not a buy or sell recommendation.

What Tenaya Therapeutics, Inc. does

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Tenaya Therapeutics is a clinical-stage biotechnology company that generates revenue primarily through strategic research and development collaborations. The company focuses on discovering and developing genetic medicines for heart disease, currently operating as a pre-commercial entity that relies on capital raises and partnership milestones to fund its operations.

Products and services

  • The company is developing a pipeline of gene therapies for heart disease, including lead clinical-stage candidates TN-201 for MYBPC3-associated hypertrophic cardiomyopathy and TN-401 for PKP2-associated arrhythmogenic cardiomyopathy.

Customer types

Biopharmaceutical companies.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations (CMOs) — The company relies on third-party contract manufacturing organizations for the production of clinical trial materials and drug candidates; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Alnylam Pharmaceuticals — A strategic collaboration agreement under which Tenaya conducts research and development activities and is eligible for upfront and milestone payments. Source

Competitors and product-market comparisons

  • Gene therapy developers — Various biotechnology and pharmaceutical companies developing gene therapies for cardiovascular indications. Source

Business strengths to evaluate

  • Proprietary gene therapy platform Source
  • Experienced management team in cardiovascular drug development Source

Business risks and research considerations

  • History of operating losses and expectation of future losses Source
  • Dependence on third-party manufacturers for clinical supply Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source · Alnylam Pharmaceuticals

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

TNYA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.57
Market capitalization:
123.69M (currency not supplied)
Revenue:
USD 1.34M
Net income:
USD -103.12M
Free cash flow:
USD -68.88M
Cash:
USD 78.09M
Total debt:
USD 3.95M
EPS:
USD -0.53

What stands out

  • Free cash flow is USD -68.88M, negative for the stored period.
  • The balance sheet shows USD 78.09M of cash versus USD 3.95M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Free cash flow is -5159.7% of stored revenue. This is a simple cross-field ratio, not a verified same-period cash conversion margin; confirm reporting periods before comparison.
  • Net income equals -7724.0% of stored revenue. This is an indicative ratio only; accounting periods and units should be verified in filings.
  • Cash exceeds debt by USD 74.14M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for TNYA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can TNYA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is TNYA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for TNYA to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of TNYA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research TNYA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.